Tributary Capital Management LLC Cuts Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Tributary Capital Management LLC trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 6.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 750 shares of the biotechnology company’s stock after selling 50 shares during the period. Tributary Capital Management LLC’s holdings in United Therapeutics were worth $265,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in United Therapeutics by 4.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock worth $391,459,000 after purchasing an additional 45,566 shares in the last quarter. FMR LLC lifted its holdings in shares of United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after buying an additional 314,004 shares in the last quarter. Pacer Advisors Inc. boosted its position in shares of United Therapeutics by 0.9% during the third quarter. Pacer Advisors Inc. now owns 566,703 shares of the biotechnology company’s stock worth $203,078,000 after acquiring an additional 4,869 shares during the last quarter. Janus Henderson Group PLC grew its stake in United Therapeutics by 12.3% during the third quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock valued at $164,978,000 after acquiring an additional 50,409 shares in the last quarter. Finally, Assetmark Inc. increased its holdings in United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after acquiring an additional 152,249 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on UTHR. Oppenheimer increased their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. TD Cowen raised their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. The Goldman Sachs Group raised their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. Finally, UBS Group upped their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $378.36.

Insider Activity at United Therapeutics

In other news, Director Nilda Mesa sold 224 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $412.28, for a total transaction of $92,350.72. Following the transaction, the director now owns 5,783 shares in the company, valued at approximately $2,384,215.24. This trade represents a 3.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,485,785.60. This trade represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 146,848 shares of company stock worth $55,165,099 in the last 90 days. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Stock Performance

UTHR opened at $370.83 on Friday. The stock’s 50 day moving average price is $365.19 and its 200-day moving average price is $355.84. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82. The stock has a market cap of $16.56 billion, a price-to-earnings ratio of 16.29, a P/E/G ratio of 0.95 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics’s quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.38 EPS. As a group, analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.